246 related articles for article (PubMed ID: 23537249)
1. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 7-tetrahydropyran-2-yl chromans: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β-protein (Aβ) in the central nervous system.
Thomas AA; Hunt KW; Volgraf M; Watts RJ; Liu X; Vigers G; Smith D; Sammond D; Tang TP; Rhodes SP; Metcalf AT; Brown KD; Otten JN; Burkard M; Cox AA; Do MK; Dutcher D; Rana S; DeLisle RK; Regal K; Wright AD; Groneberg R; Scearce-Levie K; Siu M; Purkey HE; Lyssikatos JP; Gunawardana IW
J Med Chem; 2014 Feb; 57(3):878-902. PubMed ID: 24397738
[TBL] [Abstract][Full Text] [Related]
3. 8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors.
Thomas AA; Hunt KW; Newhouse B; Watts RJ; Liu X; Vigers G; Smith D; Rhodes SP; Brown KD; Otten JN; Burkard M; Cox AA; Geck Do MK; Dutcher D; Rana S; DeLisle RK; Regal K; Wright AD; Groneberg R; Liao J; Scearce-Levie K; Siu M; Purkey HE; Lyssikatos JP
J Med Chem; 2014 Dec; 57(23):10112-29. PubMed ID: 25411915
[TBL] [Abstract][Full Text] [Related]
4. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing.
Liu X; Wong H; Scearce-Levie K; Watts RJ; Coraggio M; Shin YG; Peng K; Wildsmith KR; Atwal JK; Mango J; Schauer SP; Regal K; Hunt KW; Thomas AA; Siu M; Lyssikatos J; Deshmukh G; Hop CE
Drug Metab Dispos; 2013 Jul; 41(7):1319-28. PubMed ID: 23584887
[TBL] [Abstract][Full Text] [Related]
6. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.
Rueeger H; Lueoend R; Rogel O; Rondeau JM; Möbitz H; Machauer R; Jacobson L; Staufenbiel M; Desrayaud S; Neumann U
J Med Chem; 2012 Apr; 55(7):3364-86. PubMed ID: 22380629
[TBL] [Abstract][Full Text] [Related]
7. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.
Atwal JK; Chen Y; Chiu C; Mortensen DL; Meilandt WJ; Liu Y; Heise CE; Hoyte K; Luk W; Lu Y; Peng K; Wu P; Rouge L; Zhang Y; Lazarus RA; Scearce-Levie K; Wang W; Wu Y; Tessier-Lavigne M; Watts RJ
Sci Transl Med; 2011 May; 3(84):84ra43. PubMed ID: 21613622
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
Dineen TA; Weiss MM; Williamson T; Acton P; Babu-Khan S; Bartberger MD; Brown J; Chen K; Cheng Y; Citron M; Croghan MD; Dunn RT; Esmay J; Graceffa RF; Harried SS; Hickman D; Hitchcock SA; Horne DB; Huang H; Imbeah-Ampiah R; Judd T; Kaller MR; Kreiman CR; La DS; Li V; Lopez P; Louie S; Monenschein H; Nguyen TT; Pennington LD; San Miguel T; Sickmier EA; Vargas HM; Wahl RC; Wen PH; Whittington DA; Wood S; Xue Q; Yang BH; Patel VF; Zhong W
J Med Chem; 2012 Nov; 55(21):9025-44. PubMed ID: 22468684
[TBL] [Abstract][Full Text] [Related]
9. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).
Dineen TA; Chen K; Cheng AC; Derakhchan K; Epstein O; Esmay J; Hickman D; Kreiman CE; Marx IE; Wahl RC; Wen PH; Weiss MM; Whittington DA; Wood S; Fremeau RT; White RD; Patel VF
J Med Chem; 2014 Dec; 57(23):9811-31. PubMed ID: 25363711
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors.
Volgraf M; Chan L; Huestis MP; Purkey HE; Burkard M; Geck Do M; Harris J; Hunt KW; Liu X; Lyssikatos JP; Rana S; Thomas AA; Vigers GP; Siu M
Bioorg Med Chem Lett; 2014 Jun; 24(11):2477-80. PubMed ID: 24780121
[TBL] [Abstract][Full Text] [Related]
13. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S
J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077
[TBL] [Abstract][Full Text] [Related]
14. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
[TBL] [Abstract][Full Text] [Related]
15. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.
Borghys H; Jacobs T; Van Broeck B; Dillen L; Dhuyvetter D; Gijsen H; Mercken M
J Alzheimers Dis; 2014; 38(1):39-48. PubMed ID: 23948925
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
18. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
19. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
20. Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease.
Chen JJ; Liu Q; Yuan C; Gore V; Lopez P; Ma V; Amegadzie A; Qian W; Judd TC; Minatti AE; Brown J; Cheng Y; Xue M; Zhong W; Dineen TA; Epstein O; Human J; Kreiman C; Marx I; Weiss MM; Hitchcock SA; Powers TS; Chen K; Wen PH; Whittington DA; Cheng AC; Bartberger MD; Hickman D; Werner JA; Vargas HM; Everds NE; Vonderfecht SL; Dunn RT; Wood S; Fremeau RT; White RD; Patel VF
Bioorg Med Chem Lett; 2015 Feb; 25(4):767-74. PubMed ID: 25613679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
